UNSPSC 51173217: Calcium pantothenate/danthron/docusate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173217 Calcium pantothenate/danthron/docusate is a Commodity code with minimal alignment to recent state and local procurement activity. The single recent opportunity tagged under this code—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—involves laboratory testing infrastructure, staffing, and analytical services rather than pharmaceutical products or compounds. The scope includes immunoassay screening with LC/MS/MS or GC/MS confirmation, operation of an Interactive Voice Response system for test notifications, electronic result reporting, and alternative testing methodologies such as oral fluid and hair testing, with no direct procurement of the chemical compounds the code nominally describes. The estimated contract value is $600,000 over two years commencing September 1, 2026, with three optional one-year renewal periods.

The mismatch between the code's pharmaceutical scope and the actual work being solicited suggests that either the county's tagging is incorrect or the code sees negligible activity in state and local procurement for the calcium pantothenate, danthron, and docusate combination it nominally covers. Collin County, Texas is the sole recent issuing body on record under this code. The RFP was posted September 25, 2026, with a response deadline of July 23, 2026 (a date in the past relative to the posting date, indicating a data inconsistency in the source). Award is anticipated August 10, 2026. The county reserves the right to award in whole or in part to multiple vendors and will select the responsible contractor whose proposal represents the best evaluated offer based on vendor understanding, firm qualifications, client references, cost, and optional Phase 2 demonstrations. Prospective vendors must maintain lab certification from SAMHSA, TX DPS, or CAP.